Please login to the form below
Atopic dermatitis
This page shows the latest Atopic dermatitis news and features for those working in and with pharma, biotech and healthcare.
Sanofi reports a profit in Q4 as Dupixent sales climb
Sanofi attributed Dupixent’s growth in 2020 to continued demand in atopic dermatitis among adult and adolescent patients, as well as ‘rapid adoption’ of the drug in children.
Latest news
-
Sanofi gains access to antibody tech with Kymab acquisition
The mAb recently met both primary endpoints in a phase 2a study in moderate-to-severe atopic dermatitis patients whose disease is inadequately controlled by topical corticosteroids.
-
Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout
PDE 4 inhibitors are already used to treat inflammatory diseases in the lungs and skin, such as Amgen’s Otezla (apremilast) for psoriasis and Pfizer’s Eucrisa (crisaborole) for atopic dermatitis.
-
Menlo slumps as itching drug fails mid-stage trial
It’s not the first time that serlopitant has been undermined by a high placebo response rate in trials, however, as the drug previously missed the mark in atopic dermatitis – much
-
Tocagen merges with Forte Biosciences after brain cancer fail
set to begin in mid-2020 in adults and paediatrics with atopic dermatitis. ... Our team and advisors are committed to providing new treatment options, particularly for paediatrics with atopic dermatitis, for which few treatment options exist, and we look
-
Incyte’s JAK inhibitor cream clears second eczema trial
Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... The trials recruited patients with mild-to-moderate atopic
Sanofi gains access to antibody tech with Kymab acquisition
Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout
Menlo slumps as itching drug fails mid-stage trial
Tocagen merges with Forte Biosciences after brain cancer fail
Incyte’s JAK inhibitor cream clears second eczema trial
More from news
Approximately 10 fully matching, plus 77 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.
-
Case study: See Below
We needed to pique delegates’ interest and show them a new approach to treating atopic dermatitis. ... But, how? Before diving head-first into the idea, we enlisted the help of key stakeholders within atopic dermatitis.
-
Innovation and digital health comms recognised at Communiqué Awards
The video played while the lift whisked its passengers into the congress, creating a six-minute video ‘experience’ which challenged dermatologists to change the way they treated atopic dermatitis. ... In order to target their message, the creative
-
Drug launches to watch in 2019
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis,
-
Leo has its eyes on the prize
Innovation investment. Leo has the big beasts of psoriasis and atopic dermatitis firmly in its sights and is forging ahead on the quest to tackle unmet needs in dermatology. ... Bridging the gap. Leo is tracking increases in atopic dermatitis across
20 for 2020 – Five pharma leaders to watch in 2020
Case study: See Below
Innovation and digital health comms recognised at Communiqué Awards
Drug launches to watch in 2019
Leo has its eyes on the prize
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Dr Desiree Luthman joins Verona Pharma
atopic dermatitis in the US.
-
Ziarco appoints Mike Grey to board of directors
Concerning his appointment, Grey said: “I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis
Dr Desiree Luthman joins Verona Pharma
Ziarco appoints Mike Grey to board of directors
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Atopic Dermatitis — Going Beyond the Pill
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
-
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
-
Research Partnership has published a new patient Living with Atopic Dermatitis (US) report
Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. ... An attitudinal segmentation is included to help identify the unique groups of patients Atopic Dermatitis.
-
Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report
Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US.
-
Research Partnership
Atopic Dermatitis — Going Beyond the Pill.
More from PMHub
Approximately 4 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- Assessing the value of interim analyses in clinical trials
- AstraZeneca chooses Ireland for $360m manufacturing site
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
- Beyond yoga and smoothies – providing real support for employee well-being
- Driving Healthcare Decisions with Natural Language Processing
- FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Novo Nordisk settles US insulin pricing dispute for $100m
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Onyx Health appoints Dean Forbes
- Sandoz completes acquisition of GSK’s cephalosporin business
- Public is more comfortable with health data sharing if they know it is to support breakthrough treatments and vaccines
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
- Digital technologies: Pharma’s answer to achieving net zero emissions?
- ...
